Publications: Hypofractionation

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC):...

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

Anders Widmark et al.

The Lancet Oncology: Volume 22, Issue 2, P235-245, February 01, 2021

Click here for access to the article

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer

Charles N. Catton et al.

J Clin Oncol 2017; 35: 1884–90.

Click here for access to the article

Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

Himanshu R. Lukka et al.

Int J Radiat Oncol Biol Phys. 2018 Oct 1; 102(2): 287–295

Click here for access to the article

Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer

W. Robert Lee et al.

J Clin Oncol 2016; 34:2325–32.

Click here for access to the article

Hyprofractionated Versus Conventionally Fractionated Radiation Therapy: 7-Year Outcomes From the HYPRO Trial

Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial

Luca Incrocci et al.

Lancet Oncol 2016; 17: 1061–69

Click here for access to the article

 

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes...CHHiP trial.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

David Dearnaley et al.

Lancet Oncol 2016; 17: 1047–60.

Click here for access to the article